Publication date: 12/05/2020 – E&P Code: repo.epiprev.it/1610
Authors: Paolo Chiodini1, Laura Arenare2, Maria Carmela Piccirillo2, Francesco Perrone2, Ciro Gallo1
Abstract: Background. Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumonia.
Methods/design. TOCIVID-19is an academic multicenter, single-arm, open-label, phase 2 study. All the patients are being offered a single shot of 8 mg/kg of Tocilizumab (up to a maximum of 800 mg), with an eventual second administration at the discretion of the Investigator. A companion prospective cohort includes either patients not eligible for phase 2 or subjects eligible for phase 2 but exceeding the planned sample size. 14- and 30-days lethality rates are the two co-primary endpoints in the intention-to-treat (ITT) population. Secondary objectives are to evaluate mortality and clinical improvement in the modified-ITT population of subjects who received the drug. Details of the methodological and statistical approaches are reported here reflecting the amendments impelled by the continuously increasing knowledge on COVID-19 progression and troubles in data collection.
Discussion. This paper provides details of planned statistical analyses for TOCIVID19 trial to reduce the risk of reporting bias and increase credibility of the study findings.
TOCIVID-19 trials registered in the EudraCT database with number 2020-001110-38 and in clinicaltrials.gov with ID NCT04317092.